← Back to patent-cliff list
AL-8326
Tier C — Watch / tradeAL-8326
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FGFRs, VEGFR, AURKB
Indications (approved)：Small cell lung cancer, Non-small cell lung cancer, Renal cell carcinoma, Solid tumour, Female reproductive system cancer
Regional status
US
Phase II
2022-11-01
EU
Phase II
2022-11-01
China
Phase III
2023-10-26
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of AL-8326?
Approved indications include: Small cell lung cancer, Non-small cell lung cancer, Renal cell carcinoma, Solid tumour, Female reproductive system cancer.
When does the AL-8326 patent expire?
No public expiry year is available for AL-8326 yet; this page updates once verified.
How do I get a quote for AL-8326 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02